Liu, Yang
Dong, Xu
Huo, Hong
Feng, Liyuan
Tong, Dan
Liu, Jiahui
Zhang, Hongyan
Zheng, Yingkang
Wang, Shuai
Wang, Dongyan
Funding for this research was provided by:
Natural Science Foundation of Heilongjiang Province (LH2019H113)
Innovative Team and Outstanding Talent Program of Colleges and Universities in Guangxi
Article History
Received: 8 June 2022
Accepted: 29 March 2023
First Online: 11 May 2023
Declarations
:
: The protocol has been approved, and the informed consent has been reviewed by the Ethics Committee of the Second Affiliated Hospital of Heilongjiang University of Chinese Medicine (approval number: IRB-AF/SG-18/01.0), with further monitoring routinely including the results. All participants will sign the informed consent (version date: 2021.11.19, version number: V1.1) for publication prior to enrollment, which will be kept by the designated investigator. The recruitment will start in the Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, and the feedback and withdrawal rights of participants will be permanent during the trial. All the results (papers and reports) of this study will be published in peer-reviewed journals or conference collections. Any changes that affect the protocol implementation or are beneficial or harmful to patients, including sample size and intervention plan, should be carefully discussed and submitted to the ethics committee for review. In addition, due to the high safety of this trial, no adverse reactions have occurred since the clinical use of this instrument, so this study does not involve post-test care and compensation.
: All the authors have approved the publication of this manuscript.
: The authors declare that they have no competing interests.